Differentiated thyroid carcinoma in children: Late effects of treatment and pathophysiological background in the Netherlands.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON28040

Enrollment

150

Registered

2012-05-22

Start date

2012-08-01

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Differentiated thyroid carcinoma, thyroid cancer, late effects, child In Dutch: Gedifferentieerd schildkliercarcinoom, schildklierkanker, late effecten, kind

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Differentiated thyroid carcinoma diagnosed between 1970 and 2013 at age <19 years and treated in the Netherlands.

Exclusion criteria

Exclusion criteria: No exclusion criteria have been established for the study in its entirety. However, for evaluation of late effects including quality of life the following exclusion criteria are applicable: 1. DTC as a second malignancy; 2. <5 years since diagnosis; 3. Thyroid hormone withdrawal or rhTSH <3 months before evaluation; 4. There are additional exclusion criteria for specific parts of the study.

Design outcomes

Primary

Measure	Time frame
The primary endpoint is the incidence of late effects of 131-I treatment and TSH suppressive therapy including quality of life.	—

Secondary

Measure	Time frame
Secondary outcomes are the presence of somatic mutations and relation with clinical outcome, miRNA (-146b, -181b, -21, -221, -222) expression profile, and incidence of family members with non-medullary thyroid carcinoma.	—

Contacts

Public ContactM.S. Klein Hesselink

University Medical Center Groningen Department of Endocrinology, AA31 P.O. Box 30.001

ms.kleinhesselink@umcg.nl+31 (0)50 3613962

Outcome results